A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted results- Registry ID
- NCT07499232
- Phase
- Phase 3
- Recruitment
- Enrolling participants
- Sponsor
- Janssen Research & Development, LLC
- Design
- Randomized
- Comparator
- Guselkumab; Risankizumab
- Planned enrollment
- 530
- Endpoint
- Number of Participants with Deep Remission at Week 52
Study ages: 18 Years and older. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Austria, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Slovakia, Spain, Sweden, United Kingdom, United States.
Sites marked recruiting: Austria, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Slovakia, Spain, Sweden, United Kingdom, United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Nov 15, 2028 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1